In vivo, the efficacy of ruxolitinib in a murine JAK2V617F-driven malignancy model was demonstrated by the fact that it significantly reduced splenomegaly, decreased elevated levels of circulating IL-6 and tumor necrosis factor (TNF)-α to normal, and increased survival, without causing anemia or lymphopenia [98]. This evidence concerns the gene TNF and anemia (phenotype).